The patent is the company’s third for the technology and has been registered as: ‘signal peptides, nucleic acid molecules and methods for treatment of caries’.
The core is the company’s Competence Stimulating Peptide (CSP) technology, which has received two other patents for preventing and treating dental plaque associated with conditions such as dental cavities and periodontal disease.
Combines with oral care products to fight caries
The patent claims that the technology can be incorporated into oral care products such as mouth wash and toothpaste, together with chewing gum and as a food additive, as a method of both preventing and treating caries disease.
The technology itself combines Kane’s CSP analogue peptide, which is called E2, with any combination of additional analogues - including monoclonal antibody, antibiotic and antioxidant, dependent on the specific application.
“We have demonstrated a significant synergistic inhibitory effect of combining E2 with selected antimicrobials on dental cavity-associcated Streptococci,” said Dr. Sri Madhyastrha, research and chief scientific officer at Kane Biotech.
“This shows that an oral care product containing E2 analogue with either an antibody or antibiotic will be more effective than using the analogue alone in preventing dental caries.”
According to the company, extensive studies conducted by Dr. Dennis Cvitkovitch, of the Dental Research Institute, University of Toronto, have demonstrated the ability of the CSP analogue peptide to inhibit streptococcal bio-film.
This is the bacteria that forms a film on dental enamel that can eventually lead to the formation of plaque - the primary reason for both gum and tooth decay.